Hydrophobic salts markedly diminish viscosity of concentrated protein solutions

Biotechnology and Bioengineering

Volumn 108, Issue 3, 2011, Pages 632-636

  Du, Wei ^a,b   Klibanov, Alexander M ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b TSINGHUA UNIVERSITY   (China)

Author keywords

globulin; Bovine serum albumin; Pharmaceutical excipients; Protein liquid formulations; Salts

Indexed keywords

AQUEOUS SOLUTIONS; BOVINE SERUM ALBUMINS; CONCENTRATED SOLUTION; COUNTERIONS; HIGH VISCOSITIES; INORGANIC SALTS; IONIC INTERACTION; PHARMACEUTICAL EXCIPIENT; PROTEIN AGGREGATES; PROTEIN NETWORK; PROTEIN SOLUTION; THERAPEUTIC PROTEIN; VISCOSITY REDUCTION; VISCOUS SOLUTION;

BODY FLUIDS; DYES; HYDROPHOBICITY; LIQUIDS; MONOCLONAL ANTIBODIES; PH EFFECTS; PROTEINS; SALTS; VISCOMETERS;

VISCOSITY;

ANION; BOVINE SERUM ALBUMIN; CATION; EXCIPIENT; IMMUNOGLOBULIN; INORGANIC SALT;

AQUEOUS SOLUTION; ARTICLE; CHEMICAL STRUCTURE; HYDROPHOBICITY; PROTEIN AGGREGATION; PROTEIN PROTEIN INTERACTION; VISCOSITY;

ANIMALS; BIOPHARMACEUTICS; CATTLE; CHICKENS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; IMMUNOGLOBULINS; PROTEINS; SALTS; SERUM ALBUMIN, BOVINE; SOLUTIONS; VISCOSITY;

BOVINAE;

EID: 78751480205     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.22983     Document Type: Article

References (15)

1. Adama GP, Weiner LM. 2005. Microclonal antibody therapy of cancer. Nat Biotechnol 23: 1147-1157.
2. Chari R, Jerath K, Badkar AV, Kalonia DS. 2009. Long- and short-range electrostatic interactions affect the rheology of highly concentrated antibody solutions. Pharm Res 26: 2607-2618.
3. Charter DC, Ho JX. 1994. Structure of serum albumin. Adv Protein Chem 45: 153-203.
4. Danni B, Platz R, Tzannis ST. 2007. High concentration formulation feasibility of human immunoglobulin G for subcutaneous administration. J Pharm Sci 96: 1504-1517.
5. Frokjaer S, Otzen DE. 2005. Protein drug stability: A formulation challenge. Nat Rev Drug Discov 4: 298-306.
6. Harris RJ, Shire SJ, Winter C. 2004. Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies. Drug Dev Res 61: 137-154.
7. Kanai S, Liu J, Patapoff TW, Shire SJ. 2008. Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab-interaction that impacts solution viscosity. J Pharm Sci 97: 4219-4227.
8. Kivity S, Katz U, Daniel N, Nussinovitch U, Papageorgiou N, Shoenfeld Y. 2010. Evidence for the use of intravenous immunoglobulins-A review of the literature. Clin Rev Allerg Immun 38: 201-269.
9. Liu J, Nguyen MD, Andya JD, Shire SJ. 2005. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci 94: 1928-1940.
10. Loertscher R. 2002. The utility of monoclonal antibody therapy in renal transplantation. Transpl Proc 34: 797-800.
11. Miller MA, Engstrom JD, Ludher BS, Johnston KP. 2010. Low viscosity highly concentrated injectable nonaqueous suspensions of lysozyme microparticles. Langmuir 26: 1067-1074.
12. Paulekuhn GS, Dressman JB, Saal C. 2007. Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book database. J Med Chem 50: 6665-6672.
13. Saluja A, Badkar AV, Zeng DL, Kalonia DS. 2007. Ultrasonic rheology of a monoclonal antibody (IgG2) solution: Implications for physical stability of proteins in high concentration formulations. J Pharm Sci 96: 3181-3195.
14. Shire SJ, Shahrokh Z, Liu J. 2004. Challenges in the development of high protein concentration formulations. J Pharm Sci 93: 1390-1402.
15. Yang MX, Shenoy B, Disttler M, Patel R, McGrath M, Pechenov S, Margolin AL. 2003. Crystalline monoclonal antibodies for subcutaneous delivery. Proc Natl Acad Sci USA 100: 6934-6939.